EIKN (NASDAQ:EIKN) Coverage Initiated by Analysts at Cantor Fitzgerald

Equities researchers at Cantor Fitzgerald assumed coverage on shares of EIKN (NASDAQ:EIKN) in a research note issued to investors on Monday. The firm set an “overweight” rating on the stock.

EIKN has been the subject of a number of other reports. Morgan Stanley initiated coverage on shares of EIKN in a research note on Monday. They issued an “overweight” rating and a $32.00 target price for the company. Mizuho started coverage on EIKN in a report on Monday. They set an “outperform” rating and a $26.00 price objective on the stock. JPMorgan Chase & Co. began coverage on EIKN in a research note on Monday. They issued an “overweight” rating and a $29.00 target price for the company. Bank of America started coverage on EIKN in a research note on Monday. They set a “buy” rating and a $34.00 price target on the stock. Finally, Wedbush assumed coverage on EIKN in a research report on Thursday. They issued an “underperform” rating and a $7.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, EIKN presently has a consensus rating of “Moderate Buy” and an average price target of $25.60.

EIKN Stock Up 3.8%

Shares of EIKN stock traded up $0.52 during trading on Monday, reaching $14.30. The company’s stock had a trading volume of 101,544 shares, compared to its average volume of 393,884. EIKN has a one year low of $13.28 and a one year high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.